CIB1R peptide and related cationic sequences reduce lung cancer cell migration and invasion in vitro
Background
Lung cancer, particularly non-small cell lung cancer (NSCLC), is characterized by its high metastatic potential, which is a primary driver of poor clinical outcomes. Current therapeutic strategies often struggle to effectively target and prevent tumor cell migration and invasion, highlighting a critical need for novel modulators. The CIB1R peptide, derived from the cytoplasmic domain of neprilysin (NEP), has been proposed as a potential candidate to interfere with these metastatic processes, offering a new avenue to explore mechanisms regulating tumor progression.
Study Design
Researchers evaluated the effects of CIB1R and structurally related peptides on A549 non-small cell lung cancer cells. Peptides were administered under serum-free conditions. Cell viability was assessed using the Alamar Blue assay. Cell migration and invasion were quantified via Transwell (Boyden chamber) assays, while cell adhesion was measured on Matrigel-coated surfaces. Peptide localization was investigated using flow cytometry and confocal microscopy with FITC-labeled peptides. Membrane integrity was evaluated by propidium iodide exclusion. Statistical analysis employed one-way ANOVA followed by Tukey post hoc test.
Results
CIB1R peptide significantly reduced A549 cell migration and invasion in a dose-dependent manner. This inhibitory effect occurred without significantly impacting cell viability over 24 hours. Importantly, similar inhibitory effects on migration and invasion were also observed with structurally related peptides, including a scrambled control sequence. This suggests the observed activity is not strictly sequence-specific. All tested peptides demonstrated strong cell-associated fluorescence signals, indicating interaction with or uptake by cells. However, the experimental design could not definitively distinguish between membrane-associated and intracellular localization. No significant increase in membrane permeability was detected under the conditions tested.
CIB1R reduced cell migration and invasion in A549 cells in a dose-dependent manner without significantly affecting cell viability.
Key Findings
- CIB1R peptide reduced A549 lung cancer cell migration in a dose-dependent manner.
- CIB1R peptide inhibited A549 lung cancer cell invasion in a dose-dependent manner.
- Similar anti-migratory and anti-invasive effects were observed with structurally related peptides, including a scrambled control.
- CIB1R and related peptides did not significantly affect A549 cell viability over 24 hours.
- Peptides showed strong cell-associated fluorescence, but localization (membrane vs. intracellular) was not definitively determined.
Why It Matters
This study provides initial evidence that short cationic peptides, including CIB1R, can modulate critical cellular behaviors associated with lung cancer metastasis. The finding that non-sequence-specific, structurally related peptides also exert similar effects is a significant insight. This suggests that the anti-migratory and anti-invasive properties might stem from general physicochemical characteristics of these cationic peptides, such as charge or membrane interaction, rather than a specific receptor-mediated mechanism. Future peptide design for anti-metastatic agents could focus on optimizing cationic properties rather than solely on specific amino acid sequences, potentially leading to broader-spectrum or more robust interventions. However, further in vivo studies are needed to translate these in vitro findings into a usable protocol.
cib1r
lung-cancer
metastasis
cell-migration
cell-invasion
in-vitro